AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aquestive Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.83+0.05 (+1.32%)
Close on Oct 19, 2026
- Market cap
- $478.73M
- P/E (TTM)
- –
- Dividend yield
- –
Aquestive Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacture and supply revenue | $44.15M | $41.83M | $40.23M | $38.91M | $38.11M | $36.65M | $39.98M | $40.31M | $41.05M | $44.56M | $43.81M | $41.73M | 81.6% | +15.9% |
| License and royalty revenue (a) | $8.61M | $8.12M | $3.52M | $3.50M | $4.62M | $15.00M | $15.35M | $16.39M | $15.33M | $5.59M | $5.38M | $4.42M | 15.9% | +86.3% |
| Co-development and research fees | $1.32M | $1.12M | $1.28M | $1.37M | $1.56M | $1.94M | $1.93M | $1.99M | $1.98M | $1.35M | $1.40M | $1.32M | 2.4% | -15.3% |
| Royalty | $1.00M | $938.00K | $938.00K | $2.87M | – | – | $1.01M | – | – | $1.97M | $989.00K | – | 1.8% | – |
| Proprietary product sales, net | – | – | – | – | – | – | – | – | – | – | $0 | $589.00K | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $43.75M | $37.65M | $29.60M | $29.55M | $29.95M | $34.70M | $39.93M | $42.33M | $41.70M | $39.37M | $37.10M | $34.75M | 80.9% | +46.1% |
| Ex-United States | $10.34M | $12.62M | $14.94M | $13.85M | $14.18M | $19.52M | $17.63M | $16.57M | $16.66M | $12.14M | $13.48M | $13.31M | 19.1% | -27.1% |
From the segment and revenue-disaggregation notes of Aquestive Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.